KRAS and neoplasm: Consistently, Tumor Mutational Burden (TMB) analysis showed KRAS mutations were higher in tumors with high ALDH3A1 and ALDH3B1 expression (76% and 81%, respectively) than in those with low expression (44% and 38%, respectively).